

DAFTAR PUSTAKA

1. Rahman IW, Arfani N, Tadoda JV. Deteksi Bakteri MRSA *Methicillin-Resistant Staphylococcus aureus* pada Sampel Darah Pasien Rawat Inap. *J Ilmu Alam dan Lingkung*. 2023;14(1):48–54.
2. Wulandari A, Rahmawardany CY. Perilaku Penggunaan Antibiotik di Masyarakat. *Sainstech Farma*. 2022;15(1):9–16.
3. Aiesh BM, Nazzal MA, Abdelhaq AI, Abutaha SA, Zyoud SH, Sabateen A. Impact of an antibiotic stewardship program on antibiotic utilization, bacterial susceptibilities, and cost of antibiotics. *Sci Rep*. 2023;13(1):1–9.
4. Anggita D, Nurisyah S, Wiriansya EP. Mekanisme Kerja Antibiotik: Review Article. *UMI Med J*. 2022;7(1):46–58.
5. Armal K, Ristanti N, Deswati. Evaluasi Kuantitas Penggunaan Antibiotik pada Pasien Rawat Inap Paviliun Penyakit Dalam RSI Ibnu Sina Bukittinggi. *Afiyah*. 2023;X(1).
6. Ayuni AS. Hubungan Antara Multidrug-Resistant Organisms (MDROs) dengan Mortalitas Pada Pasien Sepsis. *Universitas Andalas*; 2024.
7. Harahap HM, Seruni D, Nasution M, Munandar F. Sepsis: Kriteria Diagnosa Dan Tatalaksana. *J Implementa Husada*. 2021;2(3):305–20.
8. Iskandar A, Siska F. Analisis Hubungan Sequential Organ Failure Assessment (Sofa) Score Dengan Mortalitas Pasien Sepsis. *J Kesehat Andalas*. 2020;9(2):168.
9. WHO. Sepsis [Internet]. World Health Organizations. 2024 [cited 2025 Mar 10]. Available from: <https://www.who.int/news-room/fact-sheets/detail/sepsis>
10. La Via L, Sangiorgio G, Stefani S, Marino A, Nunnari G, Cocuzza S, et al. The Global Burden of Sepsis and Septic Shock. *Epidemiologia*. 2024;5(3):456–78.
11. Sya'bani M., Buchori M, Aminyoto M. Faktor Yang Berhubungan Dengan Sepsis Pada Pasien Anak Di RSUD Abdul Wahab Sjahranie Samarinda. *J Verdure*. 2021;3(2):27–37.
12. Kahar LA. Hubungan Antara Polimorfisme Lokus rs7041, rs4588 pada Gen Reseptor Protein Pengikat Vitamin D dengan Mortalitas Pasien Sepsis. *Universitas Andalas*; 2023.
13. Fadrian, Decroli E, Ahmad A, Kam A, Muharramah DH, Pradana G PV. In-hospital mortality and its determinant factors among patients with sepsis. *Univ med*. 2025;
14. Ceccato A, Torres A. Sepsis and community-acquired pneumonia. 2018;1–8.
15. Darkwah S, Kotey FCN, Ahenkorah J, Adutwum-ofosu KK, Donkor ES. Sepsis-Related Lung Injury and the Complication of Extrapulmonary Pneumococcal Pneumonia. *Diseases*. 2024;12(72):1–18.
16. Farhana S, Wahyuni A, Lisiswanti R, Kedokteran F, Lampung U, Anestesiologi B, et al. Sepsis pada Pneumonia : Sebuah Tinjauan Pustaka Sepsis pada Pneumonia : Literature Review. 2024;14(April):663–8.
17. Purba AKR, Mariana N, Aliska G, Wijaya SH, Wulandari RR, Hadi U, et al. The burden and costs of sepsis and reimbursement of its treatment in a developing country: An observational study on focal infections in Indonesia.

- Int J Infect Dis. 2020;96:211–8.
18. van den Berg M, van Beuningen FE, ter Maaten JC, Bouma HR. Hospital-related costs of sepsis around the world: A systematic review exploring the economic burden of sepsis. *J Crit Care*. 2022;71:154096.
 19. Kowel FCE., Lalenoh D., Laihad M. Profil Penggunaan Antibiotik pada Pasien Sepsis dan Syok Septik di Ruang Perawatan Intensif Prof. Dr. R. D. Kandou Manado. *eCl*. 2025;13(2):248–255.
 20. Nugraheni AY, Putri MS, Saputro AY. Evaluasi Ketepatan Antibiotik pada Pasien Sepsis. *Pharmacon J Farm Indones*. 2021;18(2):194–207.
 21. Jagad GS, Kusharyanti I, Purwanti NU. Efektivitas Biaya Penggunaan Antibiotik Pada Pasien Pneumonia Balita Di Instalasi Rawat Jalan Di Rumah Sakit Bhayangkara Anton Soejarwo Pontianak. *J Pharm Tanjungpura*. 2023;1(1).
 22. Khairunnisa. Gambaran Efektivitas Biaya Terapi Antibiotik Empiris Pada Pasien Sepsis Rawat Inap Penyakit Dalam RSUP Dr. M. Djamil Padang Tahun 2017. Universitas Andalas; 2019.
 23. Fadrian, Aliska G, Utami WN. The Relationship Between Appropriateness of Antibiotic Use Based on the Gyssens Algorithm and Mortality: A Retrospective Cohort Study in Indonesian Tertiary Hospital. *Acta Med Indones*. 2024;56(2):137–44.
 24. Yudhorini LT, Komalasari Y, Azrifitria, Novanti L. Evaluasi Penggunaan Antibiotik Pada Pasien Sepsis dengan COVID-19 di Rumah Sakit Umum Pusat Fatmawati Jakarta Periode Januari – Desember 2021. *J Farm Klin Base Pract*. 2022;1(1):1–13.
 25. Langi R, Lolo WA, Jayanto I. Analisis Efektivitas Biaya Penggunaan Antibiotik Pada Pasien Sepsis Di Rumah Sakit Siloam Manado. *Pharmacon*. 2019;8(4):836.
 26. Rasmaladewi R, Sanuddin M, Shaleha M. Analisis Efektivitas Biaya Penggunaan Antibiotik Ceftriaxone Dan Ampicilin Pada Pasien Pneumonia Anak Rawat Inap Di Rsud Raden Mattaher Jambi Tahun 2018. *J Healthc Technol Med*. 2020;6(2):616.
 27. Walujo DS, Juwita NNC. Analisis Efektivitas Biaya Antibiotik Levofloxacin Dan Cefixime Pada Pasien Pneumonia Rawat Inap Di Rs Muhammadiyah Ahmad Dahlan Kediri Tahun 2022 Cost Effectiveness Analysis of Levofloxacin and Cefixime Antibiotics in Pneumonia Patients in Hospital At Mu. *J Pharma Bhakta*. 2023;3(2):40–7.
 28. Loscalzo J, Fauci AS, Kasper DL, Hauser S, Longo D JJ. *Harrison's Principles of Internal Medicine*. 21st ed. 2022.
 29. Hatman FA, Semedi BP, Budiono B. Analisis Faktor Risiko terhadap Lama Perawatan Pasien Sepsis yang Meninggal di Ruang Perawatan Intensif RSUD Dr. Soetomo Surabaya. *JAI (Jurnal Anestesiologi Indones*. 2021;13(2):78–87.
 30. WHO. Global report on the epidemiology and burden of sepsis: Current evidence, identifying gaps and future directions. 2020.
 31. Fataya E, Fadrian, Mustafa Noer, Dwitya Elvira, Yuliarni Syafrita, Netti Suharti. Characteristics of Adult Sepsis Patients Admitted to Department of Internal Medicine, Dr. M. Djamil General Hospital, Padang, Indonesia. *Biosci Med J Biomed Transl Res*. 2023;7(3):3191–8.

32. Wicaksono A, Adisasmita A, Harijanto E. Frekuensi dan Mortalitas Pasien Sepsis dan Syok Septik di ICU Rumah Sakit Swasta Tipe B, di Tangerang Selatan Frequency of Shock Septic and Mortality Rates among Sepsis Patients in ICU of a Type B Private Hospital in South Tangerang District. *J Epidemiol Kesehat Indones*. 2022;6(1):27–36.
33. Auliya B, Putri C, Dewi SS, Soleha A, Serlina D, Anisa BW, et al. Vasopresin and Corticosteroid use in Septic Shock : A Review. *J Kedokt UNRAM*. 2024;13(4).
34. Anggraini D, Hasni D AR. Pathogenesis of Sepsis. *Sci J*. 2022;1(4):262–341.
35. Jarczак D, Kluge S, Nierhaus A. Sepsis—Pathophysiology and Therapeutic Concepts. *Front Med*. 2021;8(May):1–22.
36. Vincent JL, Abraham E, Moore FA, Kochanek PM FM. *Textbook of Critical Care*. 7th ed. Elsevier; 2017.
37. Robert Gauer, Damon Forbes, Nathan Boyer. Sepsis: Diagnosis and Management. *Am Fam Physician*. 2020;101(7):409–18.
38. Toker AK, Kose S, Turken M. Comparison of sofa score, sirs, qsofa, and qsofa + 1 criteria in the diagnosis and prognosis of sepsis. *Eurasian J Med*. 2021;53(1):40–7.
39. Ruiqiang Z, Yifen Z, Ziqi R, Wei H, Xiaoyun F. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021, interpretation and expectation. Vol. 33, *Chinese Critical Care Medicine*. 2021. 1159–1164 p.
40. Wiriansya EP, Devi Grania Amalia, Andi Husni Tanra, Julia. Manajemen Terapi Cairan pada Sepsis. *Fakumi Med J J Mhs Kedokt*. 2022;2(6):393–407.
41. Daniah NF, Hidayati PH, Mulyadi FE, Sodikah Y, Handayani H. Gambaran Kultur Bakteri dan Sensitivitas Antibiotik pada Pasien Sepsis di Rumah Sakit Ibnu Sina Periode 2019-2022. *Alami J (Alauddin Islam Medical) J*. 2024;8(1):40–8.
42. Karizki MR, Puspitasari I, Asdie RH. Rasionalitas Penggunaan Antibiotik Empirik dan Definitif pada Pasien Sepsis di Intensive Care Unit RSUP. Dr. Sardjito. *Maj Farm*. 2021;17(3):343–54.
43. Firmansyah J, Wahyuni A, Ratna MG, Carolia N, Abdul H, Provinsi M, et al. Hubungan Sensitivitas Antibiotik Terhadap Luaran Pasien Sepsis di Ruang Intensive Care Unit (ICU) RSUD Dr. H. Abdul Moeloek Provinsi Lampung Tahun 2018-2021. *Medula*. 2022;12(2):231–7.
44. Gita Yustika. Analisis Parameter Leukosit dalam Diagnosis Awal Sepsis Neonatorum Awitan Dini di RSIA Ananda Makassar. *J Heal Sci*. 2020;13(2):204–14.
45. Goldberg I, Shalmon D, Shteinvil R, Wasserman A, Berliner S, Levinson T, et al. The superiority of 72 h leukocyte descent over CRP for mortality prediction in patients with sepsis. *Clin Chim Acta*. 2021;514:34–9.
46. Ilham AR, Syauqy A, Halim S. Uji Beda Leukosit dan NLR (Neutrophil Lymphocyte-Ratio) terhadap Luaran Pasien Sepsis Rawat ICU (Intensive Care Unit) RSUD Raden Mattaher Jambi 2019 - Oktober 2022. *Joms [Internet]*. 2024;04(01):1–8. Available from: <https://ojs.unud.ac.id/index.php/eum/article/view/95928/52149>
47. Mirawati A, Deswita D, Solok Poltekkes Kemenkes Padang K. Efektivitas

- Early Warning System Score dalam Pencegahan Perburukan Pasien di Rumah Sakit. *J Kesehat Lentera 'Aisyiyah* [Internet]. 2022;5(1):568–76. Available from: <https://backup.politasumbar.ac.id/index.php/jl/article/view/125>
48. Astuti LP, Trisyani Y, Mirwanti R. Implementasi Early Warning System (Ews) dalam Mendeteksi Perburukan Akut pada Pasien Dewasa di Ruang Rawat Inap Rumah Sakit. *J Telenursing*. 2023;5(2):1590–603.
 49. Brink A, Alisma J, Verdonschot RJCG, Rood PPM, Zietse R, Lingsma HF, et al. Predicting mortality in patients with suspected sepsis at the Emergency Department; A retrospective cohort study comparing qSOFA, SIRS and National Early Warning Score. *PLoS One*. 2019;14(1):1–14.
 50. Albur M, Hamilton F, Macgowan AP. Early warning score : a dynamic marker of severity and prognosis in patients with Gram - negative bacteraemia and sepsis. *Ann Clin Microbiol Antimicrob*. 2016;1–10.
 51. Zonneveld LEEC, Wijk RJ Van, Olgers TJ, Bouma HR, Jan C. Prognostic value of serial score measurements of the national early warning score , the quick sequential organ failure assessment and the systemic inflammatory response syndrome to predict clinical outcome in early sepsis. 2022;348–56.
 52. Quinten VM, Meurs M Van, Olgers TJ, Vonk JM, Ligtenberg JJM, Maaten JC. Repeated vital sign measurements in the emergency department predict patient deterioration within 72 hours : a prospective observational study. 2018;1–12.
 53. Hsu C yi, Tsai Y hsuan, Lin C yu, Chang Y chun, Chen H cheng, Chang Y ping, et al. Application of a 72 h National Early Warning Score and Incorporation with Sequential Organ Failure Assessment for Predicting Sepsis Outcomes and Risk Stratification in an Intensive Care Unit : A Derivation and Validation Cohort Study. 2021;1–14.
 54. Fadrian. *Antibiotik, Infeksi, dan Resistensi*. 1st ed. Andalas University Press; 2023.
 55. Titiesari YD, Febriani F. Optimasi Penggunaan Antimikroba Bagi Pasien Sepsis Berdasarkan Karakteristik Farmakokinetik Dan Farmakodinamik Obat: Sebuah Tinjauan Literatur. *JFIOOnline | Print ISSN 1412-1107 | e-ISSN 2355-696X*. 2021;13(1):54–61.
 56. Torres A, Blasi F, Peetermans WE, Viegi G, Welte T. The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe : a literature review. *Eur J Clin Microbiol Infect Dis*. 2014;33(7):1065–79.
 57. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America / American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. *Clin Infect Dis*. 2007;44(2):27–72.
 58. Rum M, Muchtar F, Arif SK. Penatalaksanaan Syok Sepsis pada Pasien Community Acquired Pneumonia Pasca Stroke Iskemik dengan Disfungsi Multiorgan Management of Septic Shock in a Patient with Community Acquired Pneumonia , History of Ischemic Stroke and Multiorgan Dysfunction. *Anest dan Crit Care*. 2019;37(3):107–19.
 59. Fadrian F, Linosefa L, Ridhwan FM, Hasnah H, Ayuni AS. Multidrug-

- Resistant Organisms and Determinant Factors in Sepsis Patients. *Iran J Med Microbiol.* 2023;17(5):596–605.
60. Restyana A, Faradiba, Farida U, Wahyuni K, Pambudi RS, Toyo E., et al. *Farmakoeкономи.* Malang: Future Science; 2024.
 61. Destiani D., Milanda T, Susilawati S, Suwantika A., Pradipta IS, Halimah E, et al. Cost-effectiveness analysis of ceftazidime-levofloxacin and cefotaxime-erythromycin as empirical antibiotic combinations in respiratory infection-induced sepsis Destiani , Dika P .; Milanda , Tiana ; Susilawati , Susilawati; Suwantika , Auliya A .; Pradi. *Asian J Pharm Clin Res.* 2017;10:119–21.
 62. Maidin MA, Noor NB, Sari N, Paradise S, Evawaty, Nurung M et al. *Ekonomi Kesehatan.* Makassar: Literasi Nusantara Abadi Grup; 2022. 1–6 p.
 63. Indra P CIM, Novika F, Sehati F, Shabira FN, Maulana W, Suryamika PE et al. *Ekonomi Kesehatan.* Yogyakarta: Tahta Media Group; 2022. 3–7 p.
 64. Mahardika R. *Ekonomi Kesehatan.* Yogyakarta: Samudra Biru; 2018.
 65. Nugraheni WP, Rosyidah, Arisandi, Setyawati I, Setiyadi NA, Amin NL et al. *Ekonomi Kesehatan.* Malang: Future Science; 2024.
 66. Folland, S., Goodman, A. C., Stano, M., & Danagouliau S. *The Economics of Health and Health Care.* 7th ed. Routledge; 2024. 148–173 p.
 67. Turvey R. *Demand and Supply.* 1st ed. Routledge; 2022.
 68. McPake, B., Normand, C., Smith, S., & Nolan A. *Health Economics: An International Perspective.* 4th ed. Routledge; 2020. 32 p.
 69. Sitanggang ML. *Pedoman Penerapan Kajian Farmakoekonomi.* Jakarta: Kementerian Kesehatan RI; 2012.
 70. Citraningtyas G, Ruru RI, Nalang A. Analisis Efektifitas Biaya Penggunaan Antibiotik Sefiksim dan Sefotaksim Pasien Diare di Rumah Sakit X Tahun 2017. *JMPF.* 2019;8(4):145–52.
 71. Khoiriyah SD LK. Review Artikel: Kajian Farmakoekonomi yang Mendasari Pemilihan Pengobatan di Indonesia. *Farmaka.* 2018;6:135–42.
 72. Hastuti S, Islam Z, Amaliah Z, Ruskar D. Perbandingan Analisis Biaya Penggunaan Antibiotik Seftriakson Tunggal Dengan Kombinasi Antibiotik Lain Pada Pasien Pneumonia Komunitas. *J Sci Educ.* 2022;6(2):394–403.
 73. Faridah N, Machlaurin A, Subagijo PB. Analisis Efektivitas Biaya Penggunaan Antibiotik terhadap Pasien Sepsis Pediatrik di Rawat Inap RSD dr . Soebandi Kabupaten Jember pada Tahun 2014. *e-Jurnal Pustaka Kesehat.* 2016;4(2):255–62.
 74. Jalal SM, Jalal SH, Alabdullatif AA, Alasmakh KE, Alnasser ZH, Alhamdan WY. Evaluating Sepsis Management and Patient Outcomes: A Comprehensive Retrospective Study of Clinical and Treatment Data. *J Clin Med.* 2025;14(10):1–15.
 75. Salminen A, Kaarniranta K, Kauppinen A. Immunosenescence: the potential role of myeloid-derived suppressor cells (MDSC) in age-related immune deficiency. *Cell Mol Life Sci [Internet].* 2019;76(10):1901–18. Available from: <https://doi.org/10.1007/s00018-019-03048-x>
 76. Yusransyah, Khalawatilah C, Rindarwati AY, Stiani SN, Udin B. Analisis Efektivitas Biaya pada Pasien Sepsis yang Diberikan Terapi Antibiotik Seftriakson atau Meropenem di Intensive Care Unit RSUD Berkah

- Pandeglang Periode 2022–2023. *Sains dan Ilmu Farm.* 2025;10(1):153–67.
77. Merdji H, Long MT, Ostermann M, Herridge M, Myatra SN, De Rosa S, et al. Sex and gender differences in intensive care medicine. *Intensive Care Med* [Internet]. 2023;49(10):1155–67. Available from: <https://doi.org/10.1007/s00134-023-07194-6>
 78. Al-wadees AAN, Al-khayyat AN. The Outcome of Sepsis Patients Admitted to the Intensive Care Unit : Experience of 100 Cases. 2021;75(1):35–40.
 79. Rhodes, Andres; Evans, Laura E; Alhazzani W. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. *Crit Care Med.* 2017;45(3):486–552.
 80. Tambajong RN, Lalenoh DC, Kumaat L. Profil penderita sepsis di ICU RSUP Prof . Dr . R . D . Kandou Manado Periode Desember 2014 - November 2015. *J e-Clinic.* 2016;4(1):452–7.
 81. Bisarya R, Song X, Salle J, Liu M, Patel A, Simpson SQ. Antibiotic Timing and Progression to Septic Shock Among Patients in the ED With Suspected Infection. *Chest.* 2022;161(1):112–20.
 82. Marwasyifa N, Asmarawati TP, Setiawan F. Bloodstream Infections Leading to Sepsis : Clinical and Microbiological Profiling of Bacteremia among Hospitalized Patients in Surabaya , Indonesia. 2025;06(2):106–16.
 83. Hendriana K, Riwu P, Effendi MH, Rantam FA. A review : Virulence factors of *Klebsiella pneumonia* as emerging infection on the food chain. 2022;15:2172–9.
 84. Kim TW, Lee SU, Park B, Jeon K, Park S, Suh GY, et al. Clinical effects of bacteremia in sepsis patients with community - acquired pneumonia. 2023;1–9.
 85. Estiningsih D, Puspitasari I, Nuryastuti T. Identifikas Infeksi Multidrug-Resistant Organisms (MDRO) Pada Pasien Yang Dirawat Di Bangsal Neonatal Intensive Care Unit (NICU) Rumah Sakit. *J Manaj dan Pelayanan Farm.* 2016;6(3):243–8.
 86. Gyawali B, Ramakrishna K, Dhamoon AS. Sepsis: The evolution in definition , pathophysiology , and management. *SAGE Open Med.* 2019;7:1–13.
 87. Rhee C, Dantes R, Epstein L, Murphy D., Seymour C, Lwashyna T. Incidence and Trends of Sepsis in US Hospitals Using Clinical vs Claims Data, 2009-2014. *JAMA.* 2017;318(13):1241–9.
 88. Djuang MH, Muniro FD, Sanjaya BD, Chiuman L. Faktor Resiko Sepsis Pada Pasien Lansia di Rumah Sakit Umum Royal Prima Medan. 2022;4(3):596–603.
 89. Lee JH, Kim SH, Jang JH, Park JH, Jo KM, No TH, Jang HJ LH. Clinical usefulness of biomarkers for diagnosis and prediction of prognosis in sepsis and septic shock. *Med.* 2022;101(48).
 90. Hardianti A, Kristianto H. Faktor Risiko Mortalitas Pasien Sepsis di Instalasi Gawat Darurat : Tinjauan Sistematis. 2025;XX(1):72–9.
 91. Bermejo-martin JF, Martín-fernandez M, López-mestanza C, Duque P, Almansa R. Shared features of endothelial dysfunction between sepsis and its preceding risk factors (aging and chronic disease). :1–13.
 92. Ramita GR, Gama SI, Ramadhan AM, Penelitian L, Farmaka K, Farmasi F, et al. Hubungan Ketepatan Pemilihan Antibiotik Empiris dengan Outcome

- Terapi pada Pasien Sepsis di Instalasi Rawat Inap Beberapa Rumah Sakit. 2018;(November):20–1.
93. Bui T, Patel P, Preuss C. Sefalosporin. StatPearls Publishing. 2024.
 94. Hajj J, Blaine N, Salavaci J JD. The “Centrality of Sepsis”: A Review on Incidence, Mortality, and Cost of Care. *Healthc*. 2018;6(3):90.
 95. Salman O, Procter SR, Mcgregor C, Paul P. Systematic Review on the Acute Cost-of-illness of Sepsis and Meningitis in Neonates and Infants. 2020;39(1).
 96. Budi S, Ikawati Z, Dwiprahasto I, Nuryastuti T. Evaluasi Drug Related Problems (DRPs) Antibiotik pada Pasien Sepsis di Rumah Sakit di Yogyakarta (Evaluation of Drug Related Problems (DRPs) Antibiotic in Sepsis Patients in Hospital X at Yogyakarta). 2017;15(1):43–9.
 97. Strich JR, Heil EL, Masur H. Considerations for Empiric Antimicrobial Therapy in Sepsis and Septic Shock in an Era of Antimicrobial Resistance. *J Infect Dis*. 2020;222(Suppl 2):119–31.
 98. Kim DK, Kim S, Kang DH, Ju H, Oh DK, Lee SY, et al. Influence of underlying condition and performance of sepsis bundle in very old patients with sepsis : a nationwide cohort study. *Ann Intensive Care*. 2024;14:179.
 99. Oliveira AM, Oliveira A, Vidal R, Gonçalves-pereira J. Infectious Foci , Comorbidities and Its Influence on the Outcomes of Septic Critically Ill Patients. *Microorganisms*. 2024;12:1705.
 100. Purwanti O, Sinuraya RK, Pradipta I., Abdulah R. Analisis Minimalisasi Biaya Antibiotik Pasien Sepsis Salah Satu Rumah Sakit Kota Bandung Cost Minimization Analysis of Antibiotic Used by Sepsis Patients at a Hospital in Bandung. *J Farm Klin Indones*. 2013;2.
 101. Wannawijit S. Cost-effectiveness analysis of intravenous antibiotics for treating sepsis patients : Case study at Khu Muang Hospital. *J Thai Med Inf Assoc*. 2025;11 (1):41–8.
 102. Putri KN, Subagijo PB. Analisis Efektivitas Biaya Penggunaan Antibiotik Terhadap Pasien Sepsis Di RSD dr. Soebandi Tahun 2014-2015. *e-Jurnal Pustaka Kesehatan*. 2017;5(1):155–6.
 103. Wijaksana DS, Anggraeni N, Endriani R. Pola Bakteri dan Resistensi Antibiotik pada Pasien Sepsis di Intensive Care Unit (ICU) RSUD Arifin Achmad Provinsi Riau Periode 1 Januari – 31 Desember 2017. 2017;117–25.
 104. Ota K, Kaku N, Yanagihara K. Efficacy of meropenem and amikacin combination therapy against carbapenemase-producing *Klebsiella pneumoniae* mouse model of pneumonia. *J Infect Chemother*. 2020;26(12):1237–43.
 105. Wang R, Cosgrove SE, Tschudin-sutter S, Han JH, Turnbull AE, Hsu AJ, et al. Cefepime Therapy for Cefepime- Susceptible Extended-Spectrum β - Lactamase-Producing Enterobacteriaceae Bacteremia. *Open Forum Infect Dis*. 2016;3(3):1–4.
 106. Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, et al. Carbapenem Therapy Is Associated With Improved Survival Compared With Piperacillin- Tazobactam for Patients With Extended- Spectrum β - Lactamase Bacteremia. *Clin Infect Dis*. 2015;60(9):1319–25.
 107. Halim S V, Yulia R, Setiawan E. Penggunaan Antibakteri Golongan

Carbapenem pada Pasien Dewasa Rawat Inap Sebuah Rumah Sakit Swasta di Surabaya Carbapenem Utilization among Adults Inpatients in One Private Hospital in Surabaya. J Farm Klin Indones. 2017;6(4):267–81.

